BTK
Les inhibiteurs de la tyrosine kinase de Bruton (BTK) sont des composés qui ciblent spécifiquement et inhibent la BTK, une enzyme cruciale impliquée dans la signalisation du récepteur des cellules B et la régulation de l'angiogenèse. La BTK joue un rôle significatif dans la prolifération et la survie des cellules cancéreuses, en particulier dans les malignités hématologiques. En inhibant la BTK, ces composés peuvent perturber l'angiogenèse et la croissance tumorale, ce qui les rend précieux en thérapie anticancéreuse. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de la BTK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
145 produits trouvés pour "BTK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
ARQ 531
CAS :<p>ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.</p>Formule :C25H23ClN4O4Degré de pureté :98.68% - 99.63%Couleur et forme :SolidMasse moléculaire :478.93Btk inhibitor 2
CAS :<p>Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.</p>Formule :C24H25N5O3Degré de pureté :99.94%Couleur et forme :SolidMasse moléculaire :431.49AS-1763
CAS :<p>AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.</p>Formule :C33H31FN6O3Degré de pureté :≥95%Couleur et forme :SolidMasse moléculaire :578.64Orelabrutinib
CAS :<p>Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).</p>Formule :C26H25N3O3Degré de pureté :97.77% - 99.54%Couleur et forme :SolidMasse moléculaire :427.49IBT6A
CAS :<p>IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>Formule :C22H22N6ODegré de pureté :99.8% - 99.88%Couleur et forme :SolidMasse moléculaire :386.45Rilzabrutinib
CAS :<p>Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).</p>Formule :C36H40FN9O3Degré de pureté :98.28% - 99.76%Couleur et forme :SolidMasse moléculaire :665.76MT-802
CAS :<p>MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).</p>Formule :C41H41N9O8Degré de pureté :95.93% - 97%Couleur et forme :SolidMasse moléculaire :787.82Tirabrutinib hydrochloride
CAS :<p>Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.</p>Formule :C25H23ClN6O3Degré de pureté :99.04% - 99.27%Couleur et forme :SolidMasse moléculaire :490.94BTK-IN-40
CAS :<p>BTK-IN-40 (compound 375) is an inhibitor of BTK.</p>Formule :C20H25N7O2Couleur et forme :SolidMasse moléculaire :395.46Ibrutinib dimer
CAS :<p>Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).</p>Formule :C50H48N12O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :880.99DD 03-171
CAS :<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Formule :C55H62N10O8Couleur et forme :SolidMasse moléculaire :991.163Ibrutinib-biotin
CAS :<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Formule :C56H80N12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1097.39PROTAC BTK Degrader-5
<p>PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity by</p>Formule :C52H57ClFN9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :958.52DBt-10
<p>DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].</p>Formule :C68H86ClFN16O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1277.96PROTAC BTK Degrader-9
<p>PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.</p>Formule :C46H52FN13O5Masse moléculaire :885.41984Acalabrutinib enantiomer
CAS :<p>R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.</p>Formule :C26H23N7O2Degré de pureté :97.27%Couleur et forme :SolidMasse moléculaire :465.51PTD10
CAS :<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Formule :C49H51N11O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :922BTK inhibitor 17
CAS :<p>BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.</p>Formule :C25H24N6O3Degré de pureté :99.57% - 99.88%Couleur et forme :SolidMasse moléculaire :456.5FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Couleur et forme :LiquidPCI-33380
CAS :<p>PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.</p>Formule :C46H52BF2N11O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :855.8evobrutinib
CAS :<p>Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the</p>Formule :C25H27N5O2Degré de pureté :98.03% - 99.58%Couleur et forme :SolidMasse moléculaire :429.51PROTAC BTK Degrader-8
<p>PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.</p>Formule :C80H94F2N14O20P2Masse moléculaire :1670.62121BCPyr
CAS :<p>BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).</p>Formule :C58H65F2N11O8Couleur et forme :SolidMasse moléculaire :1082.224PROTAC BTK Degrader-10
CAS :<p>PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].</p>Formule :C42H49N11O4Couleur et forme :SolidMasse moléculaire :771.91GBD-9
CAS :<p>GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).</p>Formule :C44H47N9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :797.9BTK-IN-5
CAS :<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Formule :C23H32N4O5Couleur et forme :SolidMasse moléculaire :444.532PROTAC BTK Degrader-2
CAS :<p>PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].</p>Formule :C47H54F2N8O13Couleur et forme :SolidMasse moléculaire :976.97PROTAC BTK Degrader-12
CAS :<p>PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.</p>Formule :C47H54N12O4Couleur et forme :SolidMasse moléculaire :851.01PROTAC BTK Degrader-6
CAS :<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Formule :C45H47N11O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :837.92PROTAC BTK Degrader-13
<p>PROTAC BTK Degrader-13 (Compound 25) is a targeted BTK PROTAC degrader with a DC50 of 0.27 μM. It inhibits BTK activity with an IC50 of 0.44 μM and suppresses IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. This compound also inhibits the p38 MAPK signaling pathway, thereby blocking the activation of the BCR (B cell receptor) signaling pathway. [Pink: ligand for target protein BTK ligand 15; Black: linker; Blue: ligand for E3 ligase cereblon]</p>Formule :C33H30N6O7Couleur et forme :SolidMasse moléculaire :622.63FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Couleur et forme :Odour SolidPROTAC BTK Degrader-1
CAS :<p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>Formule :C43H43N9O4Couleur et forme :SolidMasse moléculaire :749.86CNX-500
CAS :<p>CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.</p>Formule :C48H68N10O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :961.18SJF620 hydrochloride
CAS :<p>SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].</p>Formule :C41H45ClN8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :797.3Tyrosinase-IN-16
CAS :<p>Tyrosinase-IN-16 inhibited tyrosinase.</p>Formule :C8H6BrN3SDegré de pureté :99.57%Couleur et forme :SolidMasse moléculaire :256.12NRX-0492
CAS :<p>NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.</p>Formule :C43H51N11O6Couleur et forme :SolidMasse moléculaire :817.94BRK inhibitor P21d hydrochloride
CAS :<p>BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.</p>Formule :C23H23ClFN7O2Couleur et forme :SolidMasse moléculaire :483.93BTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Couleur et forme :Odour SolidBIIB091
CAS :<p>BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.</p>Formule :C28H34N10O2Couleur et forme :SolidMasse moléculaire :542.648TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Couleur et forme :Odour SolidBTK inhibitor 19
CAS :<p>BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).</p>Formule :C25H24F3N7O3Couleur et forme :SolidMasse moléculaire :527.508GDC-0834
CAS :<p>GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and</p>Formule :C33H36N6O3SCouleur et forme :SolidMasse moléculaire :596.74Anti-BTK Antibody (3G585)
<p>Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.</p>Couleur et forme :Odour LiquidPoseltinib
CAS :<p>Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.</p>Formule :C26H26N6O3Couleur et forme :SolidMasse moléculaire :470.52IBT6A hydrochloride
CAS :<p>IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.</p>Formule :C22H23ClN6OCouleur et forme :SolidMasse moléculaire :422.91Elsubrutinib
CAS :<p>Elsubrutinib (ABBV-105) is a highly active, potent, and selective orally-administered inhibitor of Bruton's tyrosine kinase (BTK). It irreversibly inhibits the catalytic domain of BTK with an IC50 value of 0.18 μM. Elsubrutinib holds potential for the advancement of research on inflammatory diseases.</p>Formule :C17H19N3O2Couleur et forme :SolidMasse moléculaire :297.358NX-5948
CAS :<p>NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.</p>Formule :C42H54N12O5Degré de pureté :98.29%Couleur et forme :SolidMasse moléculaire :806.96N-piperidine Ibrutinib hydrochloride
CAS :<p>N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.</p>Formule :C22H23ClN6ODegré de pureté :98.83%Couleur et forme :SolidMasse moléculaire :422.91Larotinib mesylate hydrate
CAS :<p>Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nM</p>Formule :C26H36ClFN4O11S2Couleur et forme :SolidMasse moléculaire :699.17RN486
CAS :<p>RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).</p>Formule :C35H35FN6O3Degré de pureté :99.38%Couleur et forme :SolidMasse moléculaire :606.69
